[Ivacaftor/tezacaftor/elexacaftor (combination with ivacaftor; cystic fibrosis, 2 to 5 years, F508del mutation, MF mutation, heterozygous) - Addendum to Project A23-122]

Institut für Qualität und Wirtschaftlichkeit im Gesundheitswesen
Record ID 32018012155
German
Original Title: Ivacaftor/Tezacaftor/Elexacaftor (Kombination mit Ivacaftor; zystische Fibrose, 2 bis 5 Jahre, F508del-Mutation, MFMutation, heterozygot) - Addendum zum Projekt A23-122
Details
Project Status: Completed
URL for project: https://www.iqwig.de/projekte/a24-43.html
Year Published: 2024
URL for published report: https://www.iqwig.de/download/a24-43_ivacaftor-tezacaftor-elexacaftor_addendum-zum-projekt-a23-122_v1-0.pdf
English language abstract: There is no English language summary available
Publication Type: Full HTA
Country: Germany
DOI: https://doi.org/10.60584/A24-43
MeSH Terms
  • Cystic Fibrosis
  • Drug Therapy, Combination
  • Child, Preschool
Keywords
  • Ivacaftor
  • Tezacaftor
  • Elexacaftor
  • Cystic fibrosis
  • Child - Preschool
  • Benefit Assessment
Contact
Organisation Name: Institute for Quality and Efficiency in Health Care (IQWiG)
Contact Address: IQWiG, Siegburger Str. 237, 50679 Cologne, GERMANY, Tel: +49(0)221-35685, Fax: +49(0)221-356851
Contact Email: berichte@iqwig.de
Copyright: Institut für Qualität und Wirtschaftlichkeit im Gesundheitswesen (IQWiG)
This is a bibliographic record of a published health technology assessment from a member of INAHTA or other HTA producer. No evaluation of the quality of this assessment has been made for the HTA database.